

Supporting Information

Hypoglycemic Activity from *Origanum vulgare* L. and major chemical constituents identified by HPLC-ESI-QTOF-MS

Huawei Yu ^{a, #}, Panpan Zhang ^{a, #}, Hongbing Liu ^b, Xiaojuan Sun^c, Jichao Liang ^a, Lijuan Sun ^{a, *}, Yong Chen ^{a, *}

^a National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei Province Key Laboratory of Biotechnology of Chinese Traditional Medicine, Hubei University, Wuhan 430062, P.R. China

^b National Centre for Magnetic Resonance in Wuhan, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan 430071, P.R. China.

^c Department of medical service, No. 923 Hospital of PLA, Nanning 530021, P.R. China.

*Corresponding author. Tel.: +86-27-88663882 (Sun L.J.), +86-27-88663590 (Chen Y.)

E-mail: lijuansun1212@163.com (Sun L.J.), cy101610@qq.com (Chen Y.)

Huawei Yu and Panpan Zhang were contributed equally to this research.

Fig. S1 The MS/MS spectrum of amburosides A




Fig. S2 The proposed fragmentation pathway of amburosides A




Fig. S3. The MS spectrum of luteolin 7-O-glucuronide




Fig. S4 The proposed fragmentation pathway of luteolin 7-O-glucuronide




Fig. S5 The MS/MS spectrum of apigenin 7-O-glucuronide




Fig. S6 The proposed fragmentation pathway of apigenin 7-O-glucuronide




Fig. S7. The MS spectrum of rosmarinic acid




Fig. S8. The proposed fragmentation pathway of rosmarinic acid




Fig. S9. The MS/MS spectrum of lithospermic acid




Fig. S10. The proposed fragmentation pathway of lithospermic acid




Fig. S11. The MS spectrum of demethylbenzolignanoid




Fig. S12. The proposed fragmentation pathway of demethylbenzolignanoid

